Welcome to our dedicated page for ALLURION TECHNOLOGIES news (Ticker: ALUR), a resource for investors and traders seeking the latest updates and insights on ALLURION TECHNOLOGIES stock.
Allurion Technologies, Inc. (NYSE: ALUR) is a medical device company focused on metabolically healthy weight loss through its Allurion Program and Allurion Smart Capsule. This news page aggregates company press releases and third-party coverage so readers can review how Allurion communicates progress on its weight-loss platform, clinical studies, regulatory milestones, and capital markets activity over time.
Company announcements frequently highlight developments related to the Allurion Smart Capsule, described as the world’s first and only swallowable, Procedureless™ gastric balloon for weight loss, and the Allurion Virtual Care Suite, which includes the Allurion Mobile App, Allurion Insights with the Iris AI Platform, and the Allurion Connected Scale. News items also cover the company’s strategic focus on metabolically healthy weight loss, including combination approaches with low-dose GLP-1 therapies and efforts to maintain or increase lean body mass in patients with overweight and obesity.
Investors and observers can use this page to follow updates on clinical evidence, such as peer-reviewed publications and case series involving the Smart Capsule, lifestyle interventions, and GLP-1 combination therapy. Allurion’s releases describe multicenter studies, case-controlled analyses, and outcomes related to weight reduction, fat mass loss, visceral fat loss, and body composition.
In addition, Allurion’s news flow includes regulatory and financial milestones, including progress in the FDA PMA process for the Allurion Smart Capsule, FDA inspections, Day-100 meetings, private placements of equity and warrants, and transactions to exchange outstanding debt for convertible preferred equity. Readers interested in ALUR news can consult this feed to see how the company reports on its operating strategy, financial results, and key risk disclosures over time.
Allurion (NYSE: ALUR) reported Q3 2025 results on November 12, 2025, with revenue of $2.7M and gross profit $1.3M (49% margin). The company said it passed FDA pre-approval inspection and BIMO audit with zero observations, entered PMA substantive review for the Allurion Smart Capsule and completed the Day-100 meeting. Allurion announced a transaction to exchange outstanding debt for convertible preferred equity and closed a $5M private placement. Q3 operating loss was $9.6M (adjusted loss $6.9M); cash was $6.1M as of September 30, 2025, excluding the private placement.
Allurion (NYSE: ALUR) reported major regulatory and financing developments on November 11, 2025. The company said it passed FDA pre-approval and BIMO inspections with zero findings and completed its Day-100 meeting, with the FDA not requesting additional human clinical data, signaling entry into the final stages of PMA review for the Allurion Smart Capsule.
Allurion also announced an exchange transaction to convert outstanding Revenue Interest Financing debt into Series B convertible preferred stock and a $5 million private placement (2,994,012 shares and warrants at $1.67 per share) to bolster working capital as it pursues FDA approval.
Allurion (NYSE: ALUR) will report third quarter 2025 financial results on Wednesday, November 12, 2025. Management will host a conference call and business update the same day at 8:30 AM ET.
To join by phone dial (888) 330-3417 (domestic) or +1 (646) 960-0804 (international) and use Conference ID 1905455. A live audio webcast will be available in the Events section of Allurion's Investor Relations website and a replay will be available by phone at (800) 770-2030 with Access Code 1905455. The archived webcast will also be posted on the Investor Relations site.
Allurion (NYSE: ALUR) published a multicenter, peer-reviewed retrospective study on October 7, 2025 reporting that two consecutive treatments with the Allurion Smart Capsule produced average 22.1% total body weight loss (19.3 kg) in 121 adults across 11 sites in six countries.
The study reported no serious device-related adverse events, aligns with the company’s FDA pivotal AUDACITY approach, and follows submission of the fourth and final PMA module to the FDA earlier in 2025.
Allurion Technologies (NYSE:ALUR), a company focused on metabolically healthy weight loss, has announced its participation in the upcoming ROTH 4th Annual Healthcare Opportunities Conference. The event will take place on October 9, 2025 at the Metropolitan Club in New York City. The company's management team will be available for one-on-one meetings with investors throughout the conference day.
Allurion Technologies (NYSE:ALUR) reported Q2 2025 financial results and announced a strategic pivot focusing on low-dose GLP-1 combination therapy. Revenue was $3.4 million, down from $11.8 million in Q2 2024, primarily due to distributor transitions. The company reported a reduced operating loss of $7.0 million, a 26% improvement year-over-year.
Key developments include a strategic partnership for manufacturing and R&D, including potential development of a GLP-1 drug-eluting balloon, and FDA acceptance of their Pre-Market Authorization application. The company ended Q2 with $12.7 million in cash and is implementing a restructuring plan expected to cost $1.5 million in Q3 2025.
The company also disclosed a potential financial restatement related to non-cash items concerning Revenue Interest Financing Agreement and convertible notes calculations.
Allurion Technologies (NYSE:ALUR), a company focused on metabolically healthy weight loss, has scheduled its second quarter 2025 financial results announcement for Wednesday, August 13, 2025.
Management will host a conference call and webcast at 8:30 AM ET to discuss the results and provide a business update. Investors can access the call via phone using the numbers (888) 330-3417 (domestic) or +1 (646) 960-0804 (international) with Conference ID 1905455. A webcast will be available in the Events section of Allurion's Investor Relations website.
Allurion Technologies (NYSE:ALUR) announced a strategic pivot focusing on low-dose GLP-1 combination therapy and muscle mass maintenance. The company has signed a term sheet with a strategic partner for expanding distribution and R&D, including potential development of a novel GLP-1 drug-eluting balloon.
Key developments include: submission of a protocol for a multi-center trial combining Allurion Program with low-dose GLP-1s, transition to distribution partners with GLP-1 prescription networks, and FDA acceptance of PMA application. Real-world data from 20,000 patients shows successful weight loss maintenance and muscle mass increases. Clinics piloting the combination approach grew 20% QoQ in Q2 2025.
Preliminary Q2 2025 results show $3 million revenue and $7 million operating loss, with operating expenses reduced by 50% YoY.
Allurion Technologies (NYSE: ALUR) has released new data demonstrating long-term effectiveness of the Allurion Program for weight loss. Two significant studies revealed impressive results:
The first study of 522 patients showed an average weight loss of 32 pounds (14.4kg) after four months, with 95% weight maintenance one year after balloon removal. The second study involving 497 patients demonstrated a 14.3% total body weight reduction, with 86% of patients maintaining weight loss after one year.
The company's AI-powered Virtual Care Suite supports sustainable weight loss through behavioral change, reinforcing Allurion's commitment to metabolically healthy weight loss solutions.
Allurion Technologies (NYSE:ALUR) has announced a strategic distribution partnership with Minogue Medical Inc. in Canada to advance metabolically healthy weight loss solutions. The partnership leverages Minogue Medical's 40-year experience and extensive network of dietitians, bariatric surgeons, and endoscopic specialists across Canada.
The collaboration aims to increase access to the Allurion Program combined with GLP-1 therapy, focusing on sustainable weight loss while maintaining muscle mass. Minogue Medical's established infrastructure and expertise in bariatric and obesity care will help implement Allurion's approach through a medically supervised, evidence-based framework.